2cureX, a IVD Diagnostic company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announces that the Chairman of the Board of Directors and and Executive Management have purchased shares in the company.
The following share purchases have been conducted:
|Shares purchased||Total shareholding|
|Povl-Andre’ Bendz||Chairman of the Board||4,775||194,033|
|Kenneth G. Johansen||CFO||4,000||4,000|